Design, Synthesis, and Biological Evaluation of Heterocyclic-Fused Pyrimidine Chemotypes Guided by X-ray Crystal Structure with Potential Antitumor and Anti-multidrug Resistance Efficacy Targeting the Colchicine Binding Site
Journal of Medicinal Chemistry · 09.03.2023 · 66 (5) · 3588-3620
DOI: 10.1021/acs.jmedchem.2c02115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 21.02.2023. Verfasst von Lun Tan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network,…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China, Natural Science Foundation of Sichuan Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Herein, a series of quinazoline and heterocyclic fused pyrimidine analogues were designed and synthesized based on the X-ray co-crystal structure of lead compound 3a, showing efficacious antitumor activities. Two analogues, 15 and 27a, exhibited favorable antiproliferative activities, which were more potent than lead compound 3a by 10-fold in MCF-7 cells. In addition, 15 and 27a exhibited potent antitumor efficacy and tubulin polymerization inhibition in vitro. 15 reduced the average tumor volume by 80.30% (2 mg/kg) in the MCF-7 xenograft model and 75.36% (4 mg/kg) in the A2780/T xenograft model, respectively. Most importantly, supported by structural optimization and Mulliken charge calculation, X-ray co-crystal structures of compounds 15, 27a, and 27b in complex with tubulin were resolved. In summary, our research provided the rational design strategy of colchicine binding site inhibitors (CBSIs) based on X-ray crystallography with antiproliferation, antiangiogenesis, and anti-multidrug resistance properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, Joint Research Institution of Altitude Health, National Clinical Rese…
- Frontiers Medical Center, Tianfu Jincheng Laboratory, Chengdu 610212, Sichuan, China.
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.
- Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.
- Department of Pharmacy, Western Theater Command Hospital, Chengdu 610083, Sichuan, China.
ORCID-Profile: Jifa Zhang, Liang Ouyang, Yuxi Wang
Förderung
- Ministry of Science and Technology of the People's Republic of China
- Natural Science Foundation of Sichuan Province
- National Natural Science Foundation of China
Zitieren
APA
Tan, L., Wu, C., Zhang, J., Yu, Q., Wang, X., Zhang, L., Ge, M., Wang, Z., Ouyang, L., & Wang, Y. (2023). Design, Synthesis, and Biological Evaluation of Heterocyclic-Fused Pyrimidine Chemotypes Guided by X-ray Crystal Structure with Potential Antitumor and Anti-multidrug Resistance Efficacy Targeting the Colchicine Binding Site. Journal of Medicinal Chemistry, 66(5), 3588-3620. https://doi.org/10.1021/acs.jmedchem.2c02115
Vancouver
Tan L, Wu C, Zhang J, Yu Q, Wang X, Zhang L, et al. Design, Synthesis, and Biological Evaluation of Heterocyclic-Fused Pyrimidine Chemotypes Guided by X-ray Crystal Structure with Potential Antitumor and Anti-multidrug Resistance Efficacy Targeting the Colchicine Binding Site. Journal of Medicinal Chemistry. 2023;66(5):3588-3620. doi:10.1021/acs.jmedchem.2c02115
BibTeX
@article{Tan2023,
author = {Tan, Lun and Wu, Chengyong and Zhang, Jifa and Yu, Quanwei and Wang, Xiye and Zhang, Lele and Ge, Meiyi and Wang, Zhijia and Ouyang, Liang and Wang, Yuxi},
title = {Design, Synthesis, and Biological Evaluation of Heterocyclic-Fused Pyrimidine Chemotypes Guided by X-ray Crystal Structure with Potential Antitumor and Anti-multidrug Resistance Efficacy Targeting the Colchicine Binding Site},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {5},
pages = {3588--3620},
doi = {10.1021/acs.jmedchem.2c02115}
}
EUVIMED